Xilio Therapeutics Inc Dossier
Qualitative Analysis
Business overview
Xilio Therapeutics, Inc. (Nasdaq: XLO) is a clinical-stage biotechnology company pioneering the development of tumor-activated, "masked" immuno-oncology (I-O) therapies. Utilizing its proprietary platform, Xilio engineers antibodies, cytokines, and other biologics designed to remain inactive in systemic circulation and selectively activate within the protease-rich tumor microenvironment. This geographically precise approach aims to maximize anti-tumor efficacy while minimizing the severe systemic toxicities historically associated with conventional I-O agents. The company's clinical pipeline includes XTX501 (a bispecific PD-1 / masked IL-2), efarindodekin alfa (masked IL-12, partnered with Gilead Sciences), and vilastobart (masked anti-CTLA-4).
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing XTX501, a bispecific PD-1 / masked IL-2 agent, through IND-enabling studies toward clinical trials.
Expected impact: Establishes clinical validation for Xilio's wholly-owned bispecific tumor-activated platform in metastatic non-small cell lung cancer.
Developing tumor-activated, multi-specific masked T cell engagers targeting tumor-associated antigens such as CLDN18.2, PSMA, and STEAP1 to address tumor heterogeneity and minimize systemic side effects.
Expected impact: Expands the pipeline into first-in-class and best-in-class multi-specific biologics with optimized therapeutic indexes.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Co-developing efarindodekin alfa (XTX301), a tumor-activated IL-12. Gilead holds an option to take over development after specified clinical data packages are delivered.
Terms: $43.5 million upfront payment, a $17.5 million development milestone achieved in Q3 2025, a potential $75.0 million transition fee, and up to $500.0 million in additional milestones plus tiered royalties.
Collaborating to discover and develop novel tumor-activated, antibody-based immunotherapies, including masked T cell engagers, leveraging Xilio's proprietary platform.
Terms: $52.0 million in total upfront payments (including a $10.0 million equity investment), eligibility for up to $2.1 billion in total contingent payments for option-related fees and milestones, plus tiered royalties.
Evaluating vilastobart (tumor-activated anti-CTLA-4) in combination with Roche's atezolizumab (Tecentriq) in an ongoing Phase 1/2 clinical trial for patients with advanced solid tumors and MSS colorectal cancer.
Terms: Co-funded clinical trial collaboration with shared cost-sharing payments.